An Inspirational Map West Sweden Artificial Intelligence An - - PowerPoint PPT Presentation

an inspirational map west sweden artificial intelligence
SMART_READER_LITE
LIVE PREVIEW

An Inspirational Map West Sweden Artificial Intelligence An - - PowerPoint PPT Presentation

West Sweden Artificial Intelligence An Inspirational Map West Sweden Artificial Intelligence An Inspiration Introduction sa Lindstrm, Sahlgrenska Science Park Erik Behm, Business Region Gteborg Inspirational Map of Big Data,


slide-1
SLIDE 1

West Sweden

Artificial Intelligence – An Inspirational Map

slide-2
SLIDE 2

West Sweden – Artificial Intelligence – An Inspiration

Introduction Åsa Lindström, Sahlgrenska Science Park Erik Behm, Business Region Göteborg Inspirational Map of Big Data, Machine Learning & AI Johan Hogsved, haw & co Inspirational Map of AI in Life Science Petra Apell, Aproficio AB The Map Selected Industries, Companies & Actors Next Steps

slide-3
SLIDE 3

West Sweden – Inspirational Map of

Big Data, Machine Learning & AI

slide-4
SLIDE 4

Disclosures Petra Apell Disclosures Johan Hogsved

20 years of experience in combining Tech, Business & Leadership. M.Sc. Engineering Physics, B.Sc. Business Administration. I run a company in IT-development & management consulting and a startup in robotic automation. Working as a consultant for Business Region Göteborg. 26 years of experience from Pharma, MedTech & BioTech. M.Sc Chemistry, Gothenburg University. PhD student, Chalmers University of Technology.

Serial entrepreneur. Current ventures: 10MD and Aproficio. AI experience is somewhat limited. Extensive experience from applying new technologies, e.g. eHealth and Virtual Reality, in medical applications. Working as a consultant for Sahlgrenska Science Park.

slide-5
SLIDE 5

The Mission

Create an map featuring West Sweden actors in the Big Data, Machine Learning & AI arena ”Is it possible to find 100 companies and

  • rganisations in the Gothenburg Area only?”
slide-6
SLIDE 6

Definitions used here

Big Data: The use of predictive analytics, user behavior analytics, or certain other advanced data analytics methods that extract value from data. Machine Learning: A field of computer science that gives computers the ability to learn without being explicitly programmed. Artificial Intelligence: When a machine mimics "cognitive" functions that humans associate with

  • ther human minds, such as "learning" and

"problem solving”.

slide-7
SLIDE 7

What we laughed at in 2014…

slide-8
SLIDE 8

Where we are today…

slide-9
SLIDE 9

Transport & Automotive Internet & Security Financial & ERP

Applications (verticals) Partners BIG DATA, MACHINE LEARNING & AI INSPIRATIONAL MAP – WEST SWEDEN 2018

Research & Education Incubators & Arenas Service Life Science Other verticals

slide-10
SLIDE 10
slide-11
SLIDE 11

Volvo Cars - Innovation in Transportation

slide-12
SLIDE 12

Volvo Trucks - Innovation in Transportation

slide-13
SLIDE 13

For Volvo Cars, technology should make people’s lives

  • easier. That’s why our

approach to autonomous driving is all about the people that will use them. Our future cars will be able to navigate without human input, equipped with sensors that read the surroundings, adapting to changing traffic conditions. ”Our work is about where the technology meets the customer benefit. As a starting point, we look at the demands put on customers by their

  • customers. We are focused
  • n solutions that can make

difficult, repetitive and time- consuming tasks easier for all concerned.” Hayder Wokil Autonomous & Automated Driving Director, Volvo Truck Our company originates from the safety leaders of the automotive industry. We are young as a company but

  • ur starting point builds on

robust industrial automotive solutions. We have a unique skillset from Tier 1 and OEM domain knowledge. All the way from sensors to vehicle control. We have joined forces to create an independent company offering our passion, technology, and solutions.

AI LANDSCAPE – TRANSPORT & AUTOMOTIVE

Veoneer’s ambition is to be a leading system supplier for ADAS and autonomous driving as well as a market leader in automotive safety electronics products. Veoneer has the world’s broadest automotive safety product portfolio, comprised of state-of- the-art active safety systems, restraint control systems, and brake systems.

slide-14
SLIDE 14
slide-15
SLIDE 15

Recorded Future - Innovation in Cyber Security

slide-16
SLIDE 16

You need more than just internal network data to uncover evolving and stealthy threats. We believe machine learning combined with human expertise is unrivaled at scaling the delivery of contextualized threat intelligence. ”The world’s premier platform for accumulating knowledge and building intelligence” A revolutionary, open and modular digital investigation software used by national security, defense and law enforcement agencies around the world. Halon consists of a dedicated team of doers. Together we have set out to change the landscape of email technology, by enabling service providers to tailor their perfect email infrastructure.

AI LANDSCAPE – INTERNET & SECURITY

”To err is human, they

  • say. But in the security

business, the goal is a zero fail rate, something nobody comes closer to than Irisity.” Irisity’s solution: To combine Artificial Intelligence and Machine Learning and couple it with vigilant human input.

slide-17
SLIDE 17
slide-18
SLIDE 18

AI is getting ready for healthcare. But is healthcare ready for AI?

slide-19
SLIDE 19

Traditional life science players are active in digitization

Our newly appointed Chief Digital Officer will help us transform our business model using digital technologies. To improve the way we use data in drug discovery and development, engage with patients, doctors and other

  • stakeholders. And automate our business processes.

Jim Jimenez, CEO Novartis GSK has consistently been active in the digital space, most recently looking to apply AI to drug discovery and medical device mobile apps. The impact of technology on the healthcare industry is accelerating and requires us to rethink our approach. Emma Walmsley, CEO GSK Through advanced tools like machine learning, we can understand which individualized therapies will be the most effective for improving quality of life, reducing healthcare costs, and preventing relapse and remission in specific segments of the population—all the way down to individualized care. Stuart McGuigan, CIO, J&J

slide-20
SLIDE 20

AI can create value across the value chain

R&D

  • Drug discovery
  • Drug Design
  • Clinical trials

Product & service

  • Supply & distribution
  • Product portfolio
  • Education

User experience

  • Diagnosis
  • Patient support
  • Decision support
slide-21
SLIDE 21

Approach to analyzing AI adoption levels in West Sweden

Main purpose Identify companies that address AI opportunities or apply AI technologies. Secondary purpose Catalyse the continued development of AI related life science projects. Methods Sources: www, innovation system, funding agencies, EU applications, network, virtual communities, public reports, newspapers, etc. Interviews: 10 senior developers and managers. Adoption level: 1 = Corporate strategy to address AI opportunities. 3 = Partial AI adopters or experimenters. 5 = AI adopters with proactive strategy and implemented solutions.

slide-22
SLIDE 22

Life Science

NOTE: List may not be complete, new companies are continuously added. List contains companies engaged on different levels.

slide-23
SLIDE 23

AI used in a variety of applications across the value chain

11% 16% 11% 13% 38% 11% Drug discovery & design Product / service Diagnostics Education Decision support Patient support

slide-24
SLIDE 24

AI adoption level per application

0% 20% 40% 60% 80% 100% Drug discovery & design Product / service Diagnostics Education Decision support Patient support 5 AI adopters with proactive strategy and implemented solutions 3 Partial AI adopters or experimenters 1 Corporate strategy to address AI opportunities

slide-25
SLIDE 25

Identified challenges

  • Start-ups who might have the technology, might not have access to data.
  • Which data sets are the most important ones?
  • Structure and annotate data.
  • Ownership of data - patient or company?
  • Complexity is a limiting factor
  • Sometimes difficult to show return on investment (ROI).
  • Regulatory – clash between the dynamic and the traditional approach.
slide-26
SLIDE 26

Peder Svensson, Dir Comp Chem & Biol, CIO Integrative Research Laboratories

slide-27
SLIDE 27

Drug discovery – the dominating picture

Binding assays Cell-based assays Ex vivo models Animal models Human pathophysiology In silico drug design. Virtual HTS

Big Data & AI High throughput screening (HTS)

slide-28
SLIDE 28

Starting point

ISP - a useful complement in drug discovery

Binding assays Cell-based assays Ex vivo models Animal models Human pathophysiology In silico drug design

Computational modelling at all stages, including AI methods

slide-29
SLIDE 29

Computational modelling including AI methods

Support for idea generation, Quantitative Structure-Activity

Relationships (QSAR)

Design of experiments / compound selection Visualization and interpretationof data Systems pharmacological translational modelling using

physiologically relevant, uniform and comparable data of high quality

slide-30
SLIDE 30

Artificial arms get closer to the real thing

Integrum has developed new breakthrough technology to connect bionic prostheses to the patient’s bone, nerves, and muscles. Robotic prostheses controlled via implanted neuromuscular interfaces have become a clinical reality thanks to Integrum’s

  • sseointegrated technology.

Founders: Per-Ingvar Brånemark & Richard Brånemark

“We have used osseointegration to create a long-term stable fusion between man and machine” Max Ortiz Catalan, Chalmers University of Technology.

slide-31
SLIDE 31

INCREASE VALUE AND LIMIT RISK IN R&D PROJECTS AND PORTFOLIOS

slide-32
SLIDE 32

STRATEGIC QUESTIONS & UNCERTAINTIES IN R&D

Development Market Launch PROJECT

  • 2% chance of launch
  • 1 bUSD to reach launch
  • Price pressure
  • Tougher requirements
  • Multi bUSD R&D spending
  • ROI less than 5%

PORTFOLIO

  • Targeted paitents?
  • How to develop?
  • Cost vs Speed?

  • Market size & uptake?
  • Competition?
  • Pricing?

  • Invest? What option?
  • Prioritized projects?
  • Incoming project flow?

$

slide-33
SLIDE 33

Design of options & scenarios Quantitative evaluation of value & risk Project/portfolio simulations New insights & new ideas

EVALUATE AND COMPARE OPTIONS ITERATIVELY TO MAXIMIZE VALUE AND LIMIT RISK

  • Captures all knowledge
  • incl. all complexities and

uncertainties

  • Risk optimized against

the financial outcome

  • Easy to compare options
  • Potential areas of

improvement are highlighted

  • Game-like and dynamic
slide-34
SLIDE 34

“Captario enables decision-making for drug development projects in a way I have not seen it before. It sets a new benchmark to assess the complexity and uncertainty of pharmaceutical portfolios to identify and address upcoming opportunities and gaps in the pipeline.”

Daniel Daetwyler Head Portfolio Management & Global Decision Support

slide-35
SLIDE 35

Key findings – life science There are extensive digitization activities and rapid growth across all fields in life science in the region. There are increased understanding of opportunities relating to AI applications in life science and healthcare. There is potential for increased collaborations between companies, regional Academic centers and Healthcare providers.

slide-36
SLIDE 36

In the mind of AI savvy individuals…

It is superexciting to work across the fields of medicine, technology and economy to solve the challenges healthcare face today. The buzz around AI has resulted in an increased understanding of the capabilities

  • f AI within our management team.

That is very helpful. If we can improve compound selection early in the drug discovery phase with the help of AI, we will definitely cut costs! I don´t think that clinicians will be replaced by AI

  • solutions. What we can do is to equip Doctors with

intelligent tools so they can make even better decisions. I wish more AI developers would choose to work with life science – it´s definitely a growing field!

slide-37
SLIDE 37

Change is inevitable. Progress is optional.

slide-38
SLIDE 38

Key Findings

Rapid growth in the region Found in almost every vertical Usage of technologies adapted to need The possibilities using the technology increases and the threshold to start gets lower and lower All actors are not world leading in AI – but use it to improve their current business

Internet Incubators & Arenas Internet & Secuity Transport & Automotive Partners Life Science Research & Education Financial & ERP

slide-39
SLIDE 39

CONFERENCES & MEETING SPACES

SPREADING THE WORD ➢2018-02-22 Metis Forum – Pre-Hospital ICT Arena ➢2018-04-10 GAIA Machine Learning & Data Science Conference 2018 ➢2018-04-12 Vehicle Electronics & Connected Services – Lindholmen ➢2018-04-23 Foss North ➢2018-04-24 Vitalis 2018 - E-health ➢2018-04-26 MedTech West Workshop – Invitation only ➢2018-05-21 Gothenburg Tech Week ➢2018-05-27 ISCE 2018 – International Conference on Software Engineering ➢2018-05-29 Lindholmen Software Development Day 2018 ➢2018-09-27 Park Annual 2018 – Life Science, incl. Digital Health & MedTech ➢MeetUp Machine Learning & Data Science (GBG)

slide-40
SLIDE 40

Thank you!